Insulet currently anticipates FDA clearance of its Omnipod 5 automated insulin delivery system late in the fourth quarter with a limited market release immediately upon clearance.

Last year Insulet snared two partnerships that are expected to help it continue its strong momentum in the market. The company inked agreements with both Abbott and Dexcom. The Omnipod 5 will be integrated with Abbott’s Freestyle Libre 2 CGM system. The companies said this integrated system will be designed to always remain in automated insulin delivery mode, and can be controlled through an app on a user's smartphone to manually take a dose of fast-acting insulin, or bolus, before meals for optimal performance. Additionally, the integrated platform is expected to be the first combined system with a fully disposable wearable sensor and pump.

The Omnipod 5 will also use sensor values from the Dexcom G6 and next-generation G7 CGM systems to predict glucose levels into the future and automatically adjust the insulin dose required to help reduce the occurrence of blood glucose highs and lows.